Historical Views, Conventional Approaches, and Evolving Management Strategies for Myeloproliferative Neoplasms
Year: 2015
Type: article
Abstract: The classical Philadelphia chromosome-negative myeloproliferative neoplasms (MPN), which include essential thrombocythemia, polycythemia vera, and myelofibrosis (MF), are in a new era of molecular diagnosis, ushered in by the identification of the JAK2(V617F) and cMPL mutations in 2005 and 2006, respectively, and the CALR mutations in 2013. Coupled with increased knowledge of disease pathogenesis and refined diagnostic criteria and prognostic scoring systems, a more nuanced appreciation has emerged of the burden of MPN in the United States, including the prevalence, symptom burden, and impact on quality of life. Biological advances in MPN have translated into the rapid development of novel therapeutics, culminating in the approval of the first treatment for MF, the JAK1/JAK2 inhibitor ruxolitinib. However, certain practical aspects of care, such as those regarding diagnosis, prevention of vascular events, choice of cytoreductive agent, and planning for therapies, present challenges for hematologists/oncologists, and are discussed in this article.
Authors: Brady L. Stein, Jason Gotlib, Murat Arcasoy, Marie Huong Nguyen, Neil Shah, Alison Moliterno, Catriona Jamieson, Daniel A. Pollyea, Bart Scott, Martha Wadleigh, Ross Levine, Rami Komrokji, Rebecca Klisovic, Krishna Gundabolu, Patricia Kropf, Meir Wetzler, Stephen T. Oh, Raul Ribeiro, Rita Paschal, Sanjay Mohan, Nikolai Podoltsev, Josef Prchal, Moshe Talpaz, David Snyder, Srdan Verstovsek, Ruben A. Mesa
Institutions: Northwestern University, Johns Hopkins University, Duke University, University of California, San Francisco, University of California San Diego, Dana-Farber Cancer Institute, University of Colorado Cancer Center, U-M Rogel Cancer Center, Stanford Cancer Institute, Duke Cancer Institute, The Ohio State University, Stanford University, University of Michigan, University of Colorado Denver, Fred Hutch Cancer Center, Memorial Sloan Kettering Cancer Center, University of South Florida, Fred and Pamela Buffett Cancer Center, Fox Chase Cancer Center, Roswell Park Comprehensive Cancer Center, Washington University in St. Louis, St. Jude Children's Research Hospital, University of Alabama at Birmingham, Vanderbilt University, Yale University, University of Utah, City Of Hope National Medical Center, City of Hope, The University of Texas MD Anderson Cancer Center, Mayo Clinic, Mayo Clinic in Arizona
Language: English
Subfield: Genetics
Field: Medicine
Domain: Health Sciences
Open Access status: bronze
OpenAlex ID: W1943058608